Related Experiment Video
Updated: Aug 11, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Crossroads in GDNF therapy for Parkinson's disease
Todd B Sherer1, Brian K Fiske, Clive N Svendsen
1Michael J. Fox Foundation for Parkinson's Research, New York, New York 10005, USA. tsherer@michaeljfox.org
Abstract:
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial-derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Parkinson Disease ll: Pathophysiology
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...